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Abstract
Background: Most in vitro assays of drug potency may not adequately predict the performance
in vivo. Methods to assess the persistence of antiviral activity of deoxynucleoside analogs, which
require intracellular activation to the active metabolites that can persist in cells, will be important
for designing dosages, combination regimens, and assessing treatment compliance. Using an HIV-
IIIB/TZM-bl indicator cell culture system, we assessed the ability of an inhibitor to protect cells
from infection and to delay viral rebound after removal of inhibitor from culture.
Results: The order of protection of cells from HIV-infection was 4'-Ed4T > LFD4C > DDI > D4T
> 3TC > AZT > FTC > NVP. The fold-increase in EC50 to delay viral rebound was DDI < 4'-Ed4T
< LFD4C < FTC < D4T < 3TC < NVP < AZT. The ranking of persistence of anti-HIV activity of
the inhibitors based on the two-component assay was DDI > 4'-Ed4T > LFD4C > FTC = D4T >
3TC > NVP > AZT.
Conclusion: The persistence ranking was derived from assays based on measures of single viral
replication-cycle and cumulative inhibition at multiple time-points. Therefore, a better indicator of
the pharmacodynamic property of an inhibitor. The persistence of anti-HIV activity assay may
complement in vitro potency assays to better predict in vivo performance of nucleoside analogs.
Background
Nucleoside analog reverse transcriptase inhibitors
(NRTIs) are the backbone of most highly active antiretro-
viral therapy (HAART) regimens. Most of the current
HAART regimens consist of two NRTIs plus a non-nucleo-
side reverse transcriptase inhibitor (NNRTI) or a protease
inhibitor (PI) [1]. NRTIs are phosphorylated to their tri-
phosphate metabolites in the cells and compete with nat-
ural dNTP substrates for incorporation into HIV DNA
leading to premature termination of the viral DNA chain
elongation [2]. The active metabolites could persist in
cells and the time of retention of the incorporated deoxy-
nucleotide may vary with different analogs. The activity
and toxicity of nucleoside analogs depend on both the
concentration of the intracellular metabolites and the sys-
temic pharmacokinetics. The clinical application of intra-
Published: 22 April 2009
AIDS Research and Therapy 2009, 6:5 doi:10.1186/1742-6405-6-5
Received: 8 January 2009
Accepted: 22 April 2009
This article is available from: http://www.aidsrestherapy.com/content/6/1/5
© 2009 Paintsil et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.AIDS Research and Therapy 2009, 6:5 http://www.aidsrestherapy.com/content/6/1/5
Page 2 of 10
(page number not for citation purposes)
cellular concentration is limited due to the technical
difficulties with the quantification of intracellular concen-
tration as well as the heterogeneity of cell populations.
Hence, plasma concentration of inhibitors, which does
not reflect the amount of active metabolites in target cells,
has been used as surrogate for designing dosage and mon-
itoring HIV therapy [3,4].
Peripheral blood mononuclear cells (PBMCs) are the nat-
ural target of HIV and therefore the ultimate host cells for
HIV drug metabolism studies. However, in vitro use of
PBMCs has several challenges; 1) lack of consistent sus-
ceptibility to HIV, 2) the need for stimulation of the cells
that may affect the expression of cellular kinases and the
dNTP pool size, 3) longer culture periods unfavorable for
single-cycle assays, and 4) individual differences in
PBMCs. Reporter systems have been used to overcome
some of these challenges; they allow for the evaluation of
HIV infectivity by using enzymatic reactions and demon-
strate greater reproducibility with wider dynamic ranges
[5-8].
The efficacy of a drug is predicted by its potency based on
the inhibition of virus replication in cell culture over sev-
eral days. The reliability of current measures of drug
potency to predict in vivo performance has been ques-
tioned by several investigators [9,10]. Furgeson et al.
argued that a single replication-cycle assay and measuring
of cumulative inhibition at multiple time-points may be
more robust pharmacodynamic measures [9]. Shen et al.
proposed that the instantaneous inhibitory potential (IIP)
based on the slope of the dose-response curve may better
reflect clinical potency of a drug rather than the traditional
measures like EC50 and inhibition quotient (IQ) [10]. In
their assay, NRTIs had a slope of about 1, and only agents
with slopes > 1 achieved high-level of inhibition of single-
round infectivity [10]. Since the IIP is dependent on the
slope of the dose-response curve it may not be sensitive
enough to discriminate the differences in potency among
the NRTIs that require intracellular activation for antiviral
activity.
We recently reported a persistence of anti-HIV activity
assay using HIV-IIIB/TZM-bl indicator cell culture system
[11]. The TZM-bl indicator cell line is a HeLa cell line
derivative that expresses high levels of CD4 and CCR5
along with endogenously expressed CXCR4 making it sus-
ceptible to both R5- and X4-tropic HIV viruses [12]. TZM-
bl cells contain HIV LTR-driven β-galactosidase and luci-
ferase reporter cassettes that are activated by HIV Tat
expression. We compared the persistence of anti-HIV
activity of a derivative of stavudine (D4T), 2',3'-didehy-
dro-3'-deoxy-4'-ethynylthymidine (4'-Ed4T, Festinavir),
to other analogs (AZT, D4T, and nevirapine [NVP]) [11].
AZT was more potent than 4'-Ed4T [13], however, the
anti-HIV activity of 4'-Ed4T persisted longer than that of
AZT after drug removal [11]. It was apparent that there
was no correlation between the potency and the persist-
ence of antiviral activity of an inhibitor. We have
expanded our study to include other RTIs and to further
investigate the apparent discrepancy between the potency
and the persistence of antiviral activity of an inhibitor. In
this study, we developed a two-component assay (i.e.,
protection of cells from HIV infection after drug removal
and delay in viral rebound after drug removal). The two
components are complementary and reflect the intracellu-
lar concentration and persistence of antiviral activity of an
analog. We present the persistence of anti-HIV activity, a
new pharmacodynamic parameter, which may comple-
ment other in vitro drug potency assays to better predict
in vivo performance of nucleoside analogs.
Methods
Chemicals
4'-Ed4T was synthesized in the laboratory of Hiromichi
Tanaka, School of Pharmaceutical Sciences, Showa Uni-
versity, Tokyo, Japan [14]. Elvucitabine (LFD4C) was syn-
thesized in the laboratory of T. S Lin, Yale University
School of Medicine, New Haven. Stavudine (D4T), zido-
vudine (AZT), didanosine (DDI) and nevirapine (NVP)
were purchased from Sigma-Aldrich Corp. (St. Louis,
MO). Lamivudine (3TC) and emitricitabine (FTC) were
gifts from Triangle Pharmaceutical (Durham, NC). The
purity of these compounds was verified by HPLC analysis.
All other chemicals used were of analytical grade or
higher.
Cell lines and virus
The TZM-bl indicator cell line [12], obtained from J. Kap-
pes through the AIDS Research and Reference Reagent
Program, is a HeLa cell line derivative that expresses high
levels of CD4 and CCR5 along with endogenously
expressed CXCR4. Cells were cultured at 37°C in the pres-
ence of a humidified 5% CO2 atmosphere. The HIV-1 IIIB
strain was received from Dr. John Mellors (University of
Pittsburg).
Assay for protection of cells from HIV infection after 
removal of drug from culture
The schema for the assay for protection of cells from HIV
infection is illustrated in Figure 1A; the details of the
experiments have been previously published [11]. In
brief, TZM-bl cells were plated at 5 × 103 cells per well in
a 96-well microtiter plate in 100 μl of Phenol Red Free
RPMI 1640 media and allowed to adhere for 15–18 h at
37°C prior to infection or drug treatment. After adherence
of the cells, the media was changed and the cells were
treated with various concentrations of 3TC, FTC, LFD4C,
or DDI. Each drug concentration was replicated five times
and the experiment repeated on at least three differentAIDS Research and Therapy 2009, 6:5 http://www.aidsrestherapy.com/content/6/1/5
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occasions. To determine the effective concentration of
inhibitor that inhibits 50% of viral growth (EC50), the
cells were infected with HIV-1 IIIB virus at an MOI of 0.1
at the time of drug treatment (see Figure 1A, top panel).
After 24 h of infection, the relative luciferase activity was
determined as described below. The EC50 was calculated
as the concentration of inhibitor that produced 50% of
the relative luciferase activity of the control wells with
HIV-infected cells in the absence of an inhibitor. For the
protection of cells from HIV infection, a batch of plates
was infected with HIV-1 IIIB virus after 24 h of incubation
with drug and the drug removed without replacement (see
Figure 1A, middle panel). A second batch of plates was
incubated after replacement of media without drug for 24
h then infected with virus after a second change of media
to remove any extracellular drug (see Figure 1A, bottom
panel). Thus, the second batch of plates had two-24 h
media changes without drug replacement prior to HIV
infection. The cells in each well were harvested after 24 h
of infection and lysed using luciferase assay reagent
(Promega, Madison, WI). Firefly luciferase activities were
quantified using a dual-luciferase reporter assay system
(Promega, Madison, WI), and a microplate luminometer
(FARCyte™, Amersham Biosciences Co., Piscataway, NJ).
Background luminescence was determined from unin-
fected cells and subtracted from all experimental wells.
Protection of cells from HIV infection was measured as a
function of inhibition of viral replication (% of control
replication without drug), calculated by dividing the
mean number of luciferase units at each concentration of
a drug by the mean number from cells containing no
drug. The ability of a drug to protect cells from HIV infec-
tion is illustrated on plot with percentage inhibition on
the y-axis against drug concentration on the x-axis (Figure
2).
Assay for viral rebound after removal of drug from culture
The schema for the assay for viral rebound after removal
of drug from culture is illustrated in Figure 1B. To evaluate
viral rebound after drug removal, TZM-bl cells plated at 5
× 103 cells per well, as described above, were pre-incu-
bated with various concentrations of inhibitor for 12 h at
37°C. Each drug (i.e., 4'-Ed4T, D4T, AZT, DDI, 3TC, FTC,
LFD4C, or NVP) was tested at multiplicities of the EC50.
Each drug concentration was replicated five times and the
experiment repeated on at least three different occasions.
The pre-treated cells were then infected with HIV-1 IIIB
virus at an MOI of 0.05 at time zero and incubated at
Schematic representation of persistence assays Figure 1
Schematic representation of persistence assays. (A) Assay for Protection of Cells from HIV Infection after removal of 
inhibitor, and (B) Assay for Viral Rebound after removal of inhibitor. RLU, is relative luciferase unit; wash implies the change of 
media without replacement of drug.
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37°C (Figure 1B). For the positive control experiment,
i.e., EC50 in the presence of drug, the cells were harvested
for the determination of luciferase activity after 24 h of
incubation (see Figure 1B, top panel). For the plates des-
ignated for the rebound assay, the culture media were
changed to remove extracellular drug without replace-
ment of drug at 24 and 48 h post-infection (see Figure 1B,
middle and bottom panels). At each time point, cells from
a batch of the plates were harvested and the luciferase
activity was determined as described above. Viral rebound
was determined as a function of luciferase activity similar
to that of day one of the untreated virus control.
Protection of cells from HIV infection after removal of inhibitor from culture Figure 2
Protection of cells from HIV infection after removal of inhibitor from culture. The protection of cells from HIV 
infection was determined using a TZM-bl indicator cell line based-single cycle replication assay described in the "Materials and 
Methods" section and illustrated in Figure 1A. TZM-bl cells were cultured in the presence of various concentrations inhibitor 
(LFD4C, FTC, DDI, or 3TC) 24 h. The cells were then washed to remove extracellular drug, and infected with HIV-1 IIIB virus 
at an MOI of 0.1 at 0, 24, and 48 h of drug removal. The percentage inhibition of HIV-1 replication was determined by measur-
ing the luciferase activity. The curves represent: percent inhibition of HIV-1 replication when cells were infected at the time of 
drug treatment and incubated together for 24 h (black circle); percent inhibition when cells were pre-incubated with drugs for 
24 h and the media changed without replacement of drug prior to infection and incubated for 24 h (black triangle); and percent 
inhibition when cells were pre-incubated with drugs for 24 h and then the media was changed to remove drug at 0 and 24 h 
without drug replacement prior to infection (black square). Results are the average of at least three independent experiments. 
Error bars indicate standard deviations.
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Results
Efficacy of HIV reverse transcriptase inhibitors
Traditionally, in vitro efficacies are based on cumulative
inhibition of multiple HIV replication cycles. We deter-
mined the efficacies of HIV reverse transcriptase inhibitors
in a single HIV-replication cycle assay using TZM-bl indi-
cator cell line. TZM-bl cells were infected with HIV-1 IIIB
virus at an MOI of 0.1 in the presence of test inhibitor (L-
FD4C, 3TC, FTC, or DDI) to assess the potency of each
inhibitor. The EC50 in TZM-bl cells was determined after
24 h incubation by measuring the luciferase activity as
previously described [15]. We next investigated the EC50
with pre-incubation of drug. The EC50s obtained with pre-
incubation of cells with inhibitor (4'-Ed4T, D4T, AZT,
DDI, 3TC, FTC, LFD4C, or NVP) 24 h prior to infection
are shown in Table 1. EC50s 4'-Ed4T, D4T, AZT, and NVP
have been previously published [11]; they were included
in Table 1 for comparison. The EC50s obtained with pre-
incubation of cells in our assay were more consistent with
published potencies of these analogs based on multiple
HIV replication cycles [16-19]. To our surprise, the EC50s
of NVP and AZT increased by 3- and 4-folds, respectively,
with pre-incubation. However, the potencies of 4'-Ed4T,
DDI, and LFD4C improved with pre-incubation of the
cells with the Inhibitors prior to infection. Therefore, pre-
incubation of cells with nucleoside analogs may be neces-
sary for assessing antiviral potency in single cycle HIV-rep-
lication assay.
Protection of cells from HIV infection after removal of drug 
from culture
We investigated the persistence of anti-HIV activity to pro-
tect cells from HIV infection after removal of drug from
culture. TZM-bl cells were pre-incubated with inhibitors
to ensure that all inhibitors have reached their peak intra-
cellular concentrations prior to HIV infection; this is
based on our previous report that AZT reached its peak
concentration at 2 h while d4T and 4'-Ed4T reached peak
concentrations at 12 h and other published studies
[11,20]. After 24 h of infection, the percentage of HIV-1
replication inhibition was determined by measuring the
luciferase activity [15]. When infection occurred after the
first change of media to remove extracellular drug (i.e.,
Figure 1A, at 0 h after removal of inhibitor), the inhibition
curves for all the analogs shifted to the right except for L-
FD4C, and DDI (Figure 2). When infection occurred after
two consecutive changes of media without replacing drug
(Figure 1A), only LFD4C, and DDI crossed the EC50 line;
the other inhibitors tested did not protect the cells from
HIV infection (Figure 2). None of the inhibitors currently
in use for HIV-infected individuals tested protected cells
from infection beyond 24 h of removal of drug at the
highest concentration, except for DDI [11]. All the inhib-
itors showed a dose-dependent inhibition of viral replica-
tion (Figure 2). On the average, the ability of the
inhibitors to protect cells from HIV infection after 48 h of
removal of drug from cell culture was 4'-Ed4T > LFD4C >
DDI > D4T > 3TC > AZT > FTC > NVP. The composite
ranking was obtained using previously published data on
4'-Ed4T, D4T, AZT, and NVP [11].
Viral rebound after removal of drug from cell culture
Complex dosing schedules of antiretroviral therapy (ART)
may lead to poor compliance and many patients take drug
holidays for a few days to several weeks [21,22]. With the
persistence of anti-HIV activity of 4'-Ed4T, LFD4C and
DDI, we investigated if this will translate into delay in
viral rebound after removal of inhibitor from HIV-
infected cell culture (Figure 1B). This assay simulates a sit-
uation where a patient misses a couple of days of antiret-
roviral drug. TZM-bl cells pre-treated with different
concentrations of an inhibitor were infected with HIV-1
IIIB virus at an MOI of 0.05 and incubated at 37°C. The
culture media were changed to remove extracellular drug
at 24, and 48 h post-infection without replacement of
inhibitor and cells of a batch of the plates harvested at
Table 1: Antiviral activity of HIV inhibitors with or without pre-incubation of TZM-bl cells in single-cycle assay
Inhibitor aEC50 without pre-incubation of cells 
(μM)
bEC50 with pre-incubation of cells 
(μM)
Fold-Change in EC50 with pre-
incubation
(aEC50/bEC50)
4'-Ed4Tc 1.03 ± 0.45 0.37 ± 0.15 2.8
LFD4C 0.34 ± 0.02 0.16 ± 0.08 2.1
DDI 10.2 ± 1.1 5.4 ± 0.8 1.9
D4Tc 1.08 ± 0.12 1.30 ± 0.21 0.8
FTC 0.80 ± 0.04 1.03 ± 0.23 0.8
3TC 0.40 ± 0.02 0.53 ± 0.01 0.8
NVPc 0.020 ± 0.004 0.063 ± 0.04 0.3
AZTc 0.018 ± 0.007 0.074 ± 0.040 0.2
a Concentration required to inhibit HIV-1 replication in TZM-bl cells by 50% without pre-incubation of cells with inhibitor.
b Concentration required to inhibit HIV-1 replication in TZM-bl cells by 50% when cells were pre-incubated with inhibitor 24 h prior to infection.
c The EC50 of these analogs has been previously published [11]
Results are the average of at least three independent experiments.AIDS Research and Therapy 2009, 6:5 http://www.aidsrestherapy.com/content/6/1/5
Page 6 of 10
(page number not for citation purposes)
each time point. Luciferase activity was determined as a
function of viral replication; luciferase activity similar to
that of day one of the untreated virus control was consid-
ered as viral rebound. When the culture was treated with
5 × EC50 of the inhibitor, viral rebound occurred within 24
h with D4T, 3TC, NVP, and AZT (Table 2). Viral rebound
was observed in cultures treated with 5 × EC50 of FTC and
LFD4C at 48 h. With 4'-Ed4T and DDI, viral rebound
occurred after 48 and 72 h, respectively. We observed a
dose-dependent delay of viral rebound after removal of
inhibitor from culture with 4'-Ed4T, LFD4C, D4T, NVP
and 3TC. Interestingly, AZT did not delay viral rebound
beyond 24 h even at 100 × EC50 (data not shown). In gen-
eral, inhibitors that ranked high in the ability to protect
cells from HIV infection were superior in preventing viral
rebound after removal from cell culture. None of the
inhibitors could completely prevent viral rebound after
removal from culture. This suggests that there is always
residual viral replication or the inhibition is reversible
[19].
The antiviral activity of an inhibitor follows concentra-
tion-dependent kinetics. The serum concentration should
stay well above the EC50 during the dosing interval for effi-
cacy. We, therefore, assessed the fold-increase in EC50 of
an inhibitor required to keep viral rebound at 50% of the
untreated control after removal of drug for 48 and 72 h
(Table 3). At 48 h after removal of drug, the fold-change
in concentration of inhibitor required to keep viral
rebound at 50% was in the order of DDI < 4'-Ed4T <
LFD4C < FTC < D4T < 3TC < NVP < AZT. The fold-increase
in EC50 at 72 h showed a similar order (Table 3). NVP,
3TC, and AZT required greater than 75, 150 and 1000
fold-increase, respectively, to maintain viral rebound at
50% of the untreated control. DDI, 4'- Ed4T, LFD4C and
FTC were superior in preventing viral rebound.
Persistence ranking of reverse transcriptase inhibitors
The protection of cells from HIV infection and the viral
rebound assays were complementary and are measures of
the persistence of an inhibitor after removal from cell cul-
ture. The persistence of anti-HIV activity is a function of
an inhibitor's ability to protect cells from HIV infection
and to delay viral rebound after removal from culture.
Based on the two-component assay we ranked the inhibi-
tors in the order of decreasing persistence of anti-HIV
activity: DDI > 4'-Ed4T > LFD4C > FTC = D4T > 3TC >
NVP > AZT.
Discussion
The persistence of anti-HIV activity of an inhibitor
presents a new way of looking at the pharmacodynamic
property of an inhibitor in vitro that may predict its in
vivo performance. It could complement other in vitro
measures like EC50, inhibition quotient (IQ), and the
recently described instantaneous inhibitory potential
(IIP) [10], especially with regard to nucleoside analogs.
Our two-component persistence assay combines meas-
ures of single viral replication-cycle and cumulative inhi-
bition at multiple time-points. It is a function of an
inhibitor's ability to protect cells from HIV infection and
delay viral rebound after removal of inhibitor from cell
culture. Inhibitors such as DDI, 4'-Ed4T, LFD4C, FTC, and
D4T were superior in delaying viral rebound after removal
from cell culture. The persistence of anti-HIV activity of an
inhibitor is dependent on the intracellular pool of the
inhibitor and its metabolites. Therefore, the rank order of
the inhibitors should remain the same regardless of the
cell type used. There may be inter-class differences but no
significant intra-class differences, e.g., the order within the
thymidine analogs should be reproducible across differ-
ent cell lines. The NRTIs undergo stepwise phosphoryla-
tion by intracellular kinases to their active triphosphate
metabolites; the triphosphate metabolites inhibit viral
DNA synthesis by competing with natural dNTPs as sub-
strate for viral DNA polymerase [2]. The efficiency of this
Table 2: Time to viral rebound to the level of untreated virus 
control at 24 h
Inhibitor Viral rebound (hours post wash)a
5 × EC50
b 50 × EC50
b
4'-Ed4T >48 >>72
LFD4C 48 n.d
DDI >72 n.d
D4T <24 >72
FTC 48 n.d
3TC <24 48
NVP <24 <24
AZT <24 <24
a Luciferase activity similar to that on day 1 of the untreated virus 
control was considered as viral rebound.
bEC50 based on values without preincubation.
n.d (not determined): The inhibitors were not tested at these 
concentrations either because of known cytotoxicity or unachievable 
concentration during therapy of HIV-infected individuals.
Results are the average of at least three independent experiments.
Table 3: Fold-increase in EC50 required to keep viral growth at 
50% over time
Inhibitor Fold-increase in EC50
a (± S.D)
48 h 72 h
4'-Ed4T 2.6 ± 0.4 8.6 ± 1.4
LFD4C 4.1 ± 1.2 13.5 ± 3.7
DDI 1.8 ± 0.5 2.5 ± 0.1
D4T 11.0 ± 1.2 38.4 ± 4.2
FTC 5.6 ± 0.9 >12.5b
3TC 17.3 ± 4.2 >75b
NVP 70.5 ± 14.1 >150b
AZT 127.8 ± 19.2 >1000b
aEC50 based on values without pre-incubation of the inhibitor as 
reported in Table 1, column 2.
b Maximum concentration tested at 72 h.AIDS Research and Therapy 2009, 6:5 http://www.aidsrestherapy.com/content/6/1/5
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process will depend on the expression and quality of the
cellular kinases, intracellular dNTP pool, and the analog.
For instance, different thymidine analogs have varying
affinities to thymidine kinase (TK1) [23]. Moreover, the
intracellular dNTP level varies significantly between dif-
ferent cell types and fluctuates during the cell cycle [24].
The pool of naturally occurring dNTPs is about 20-fold
higher in established T-cell lines compared to that of pri-
mary cells [25]. There are individual differences in cellular
transport and metabolism of NTRIs [26]. Taken together,
our findings using transformed cell line may not be
extrapolated to primary cells (PBMCs). However, our con-
ditions are sufficient to allow us to observe differences in
the persistence of anti-HIV activity of the inhibitors stud-
ied; our findings are, therefore, a reflection of the differ-
ences in the inhibitors. Though, the use of PBMCs for
these studies will not be trivial, further studies using
PBMCs are needed to validate the assay and the concept of
persistent index.
Traditionally, the plasma concentration of inhibitors has
been used as surrogate for designing dosage and monitor-
ing HIV therapy [3,4]. However, plasma concentration of
an inhibitor may not predict the intracellular concentra-
tion and the anti-HIV activity of an inhibitor [3,4,11,27].
The plasma elimination t1/2 of AZT, D4T, 4'-Ed4T, 3TC,
FTC, tenofovir (TDF), and abacavir (ABC) are 0.5–3, 0.8–
1.5, 2.3 to 3.7, 5–7, 8–10, 12–17, and 0.9–2.2 h, respec-
tively [28,29]. While the intracellular t1/2 of AZT, D4T,
3TC, FTC, TDF, and ABC in human PBMCs are 3–4, 7, 15–
16, 29–56, 60->175, and 12–21 h, respectively. The intra-
cellular concentration of an inhibitor is more predictive of
the anti-HIV activity of an inhibitor [30]. In our study,
inhibitors with longer intracellular half lives tended to
have superior persistence of anti-HIV activity. Witvrouw et
al. demonstrated that TDF was the only analog tested that
could delay viral rebound for 2 to 3 days after removal
from cell culture [19]. The authors attributed the ability of
TDF to delay viral rebound to its persistence in cells. This
is consistent with an in vivo study where the TDF triphos-
phate concentration was still quantifiable in PBMCs of 6
of 8 and 2 of 8 patients 14 and 28 days after the last dose
of TDF, respectively [31]. The triphosphate concentration
of ABC in patients fell to below the limit of detection in
all patients studied by 72 h after the last ABC dose. Thus,
the persistence assay is a function of the intracellular con-
centration. Moore et al. found a linear relationship
between intracellular concentration of AZT-TP and 3TC-
TP and changes in plasma HIV-1 RNA concentration [30].
Our findings are consistent with the findings of the in
vitro and in vivo studies reported above. Our persistence
assay is a surrogate measure of intracellular concentration
and anti-HIV activity of an inhibitor. Moreover, the inhib-
itors were studied using the same cell line and experimen-
tal conditions affording us the ability to compare the
persistence of anti-HIV activity of one inhibitor to the
other. Furthermore, the assay could be explored as a cost-
effective measure of intracellular concentration.
The persistence of anti-HIV activity could have several
clinical applications; selection of nucleoside analog back-
bone for combination antiretroviral therapy, selection of
appropriate pre- and post exposure prophylaxis (PrEP and
PEP), and prediction of drugs that may be more "forgiv-
ing" if a patient inadvertently takes drug holidays. Most
current HAART regimens comprise of two nucleoside ana-
logs and a non nucleoside analog or a protease inhibitor
[1]. Therefore, NRTIs continue to be an important part of
HAART. Shen et al. found that the IIP of NRTIs were ≤ 3.5
and generally less than that of NNRTI and PIs [10]. The
use of IIP to select an NRTI backbone may not be discrim-
inatory enough. Inhibitors that do not require intracellu-
lar activation for antiviral activity tended to have low IIP
values. Therefore, the persistence of anti-HIV activity assay
may be more sensitive and discriminatory for the selec-
tion of NRTI backbone of HAART. FTC delayed viral
rebound better than 3TC; fixed-dose combination with
tenofovir (TDF) has demonstrated superior efficacy in
clinical practice. The ability of FTC to delay viral rebound
is comparable to that of DDI, 4'-Ed4T, LFD4C and TDF.
Combination of two NRTIs with better persistence of anti-
HIV activity may be an ideal NRTI backbone for HAART.
4'-Ed4T, currently in clinical development, in combina-
tion with cytidine analogs has shown synergistic anti-HIV
activity in vitro [13]. The persistence of antiviral activity of
4'-Ed4T after removal of drug from culture may be due to;
1) the fact that 4'-Ed4TTP once formed remains relatively
stable and active in cells, and that the pool of 4'-Ed4TMP
may continue to replenish the critical concentration of 4'-
Ed4TTP, 2) less efficient removal of incorporated nucle-
otide by exonucleases from terminal viral DNA and 3)
inability of 4'-Ed4T metabolites to permeate the cell mem-
brane by non-facilitated diffusion (unpublished data) as
compared to the metabolites of AZT [32]. If proven to
have favorable safety profile, and efficacious in clinical tri-
als, it could be co-formulated with a cytidine analog as
HAART backbone.
Also, combination of the persistence of anti-HIV activity
and potency will have useful clinical applications. For
instance, DDI, at the current clinical dosing, is associated
with pancreatitis as a side effect [33]. DDI in our assay was
the best in delaying viral rebound. It is possible that its
persistence in certain cells (e.g., pancreatic cells) may be
responsible for the observed clinical side effects. It has
been observed that rates of pancreatitis in HIV-infected
individuals on DDI seem to have positive correlation with
dosage [33]. Therefore, the combination of the persistence
of anti-HIV activity and potency may be useful in selectingAIDS Research and Therapy 2009, 6:5 http://www.aidsrestherapy.com/content/6/1/5
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a dosage that is adequate to achieve viral suppression
while avoiding side effects (e.g., pancreatitis).
The drug persistence assay simulates the concept of HIV
pre- and post- exposure prophylaxis. Animal models show
that after initial exposure, HIV replicates within dendritic
cells of the skin and mucosa before spreading through
lymphatic vessels and developing into a systemic infec-
tion [34]. The delay in the viremic phase offers a "window
of opportunity" for PEP using antiretroviral drugs [35,36].
An antiretroviral agent with persistence of anti-HIV activ-
ity even after its removal will be ideal for PrEP or PEP. For
instance, TDF with prolong intracellular half life and abil-
ity to delay viral rebound has been found to be a useful
antiviral agent for PEP and it is being evaluated in clinical
trials for PrEP [37-39]. Therefore, 4'-Ed4T and LFD4C,
which are still in clinical development, are promising can-
didate antiviral agents for PrEP and PEP.
Residual HIV viral replication is often observed even with
currently effective drugs in treatment-experienced individ-
uals with no signs of overt disease [40,41]. An inhibitor
with a superior persistence of anti-HIV activity may be
more "forgiving" when a patient inadvertently misses a
couple of doses. We simulated a scenario where patients
may give themselves drug holidays for a few days (e.g.,
due to intercurrent illness, surgery, toxicity or unavailable
medication). The culture media were changed to remove
extracellular drug at 24, and 48 h post-infection without
replacement of inhibitor to simulate 24, and 48 h of drug
holiday, respectively. Inhibitors with longer intracellular
half-lives and/or less efficiently removed from the termi-
nal of HIV DNA delayed viral rebound longer [17,42].
Consistent with clinical observations, the time to viral
rebound correlated positively with the efficacy of the
inhibitor [42-44]. None of the inhibitors studied was able
to completely prevent viral rebound. This is consistent
with previous findings of the removal of drug pressure in
short-term in vitro assays [19]. In contrast, there have
been reports of complete clearance of HIV from virus-
infected cells after prolonged subcultivations [45,46].
Viral rebound occurred within 24 h with most of the
antiretroviral agents currently in clinical use (AZT, D4T,
3TC, and NVP) at 5 × EC50 concentrations (Table 2). With
FTC and LFD4C, cytidine analogs with longer intracellular
half-lives than 3TC, viral rebound occurred at 48 h after
removal of drug from culture. All the inhibitors, except
AZT and NVP, exhibited a dose-dependent delay in viral
rebound. Our findings of the inability of AZT to prevent
viral rebound is consistent with previous studies where
AZT at 500 ×-, and 1000 × EC50 failed to prevent viral
breakthrough beyond 24 h [19,45]. Contrary to our
expectation, NVP, which is used as a single dose to prevent
mother-to-child transmission of HIV because of its favora-
ble pharmacokinetics (t1/2 of 30 h) [47], did not delay
viral rebound at 50 × EC50. High prevalence of NVP resist-
ance mutations (e.g., K103N and Y181C) has been
reported among mothers and infants who received a sin-
gle dose NVP to prevent vertical transmission of HIV-1
[48]. Though, NVP had long plasma half-life, our findings
may suggest that the rapid evolution of NVP resistant
mutation is probably due to its poor intracellular reten-
tion. Based on the EC50, 3TC was about 2-fold potent than
FTC, however, the anti-HIV activity of FTC persisted
longer than 3TC. Therefore, the potency of an analog
based on the EC50 may not be adequate to predict its activ-
ity. FTC-TP is incorporated about10-fold more efficiently
than 3TC-TP by HIV-1 RT during RNA-dependent DNA
synthesis [49]. The degree of viral rebound may depend
on residual viral activity and the rate of removal of the
incorporated triphosphate from the viral DNA chain to
allow incorporation of natural dNTP. The delay in viral
rebound with FTC treatment may be due to the slow exci-
sion of incorporated triphosphate of FTC in comparison
with that of 3TC [49].
While we must exercise caution in drawing conclusions
on clinical effects based on data from in vitro experi-
ments, recent studies have demonstrated that current
assays may not be adequate in predicting in vitro perform-
ance of an inhibitor and therefore a need for better assays.
Ferguson et al. in a mathematical model, suggested that
the best in vitro assay to reflect in vivo effect should be
based on either single replication-cycle assays or a meas-
ure of cumulative inhibition at multiple time points [9].
Our two-component persistence assay satisfies the above
criteria and was able to detect differences in the persist-
ence of anti-HIV activity of inhibitors tested.
Conclusion
The persistence of anti-HIV activity of the inhibitors (table
4) was derived from assays based on measures of single
viral replication-cycle and cumulative inhibition at multi-
ple time-points and therefore a better indicator of the
Table 4: Persistence index and ranking of HIV inhibitors
Inhibitor aEC50(μM) bEC50(μM) Persistence Index (Pi)
(aEC50/bEC50)
DDI 18.6 ± 5.4 5.4 ± 0.8 3.4
4'-Ed4T 2.7 ± 0.1 0.37 ± 0.15 7.3
LFD4C 1.4 ± 0.4 0.16 ± 0.08 8.8
D4T 11.9 ± 1.0 1.30 ± 0.21 9.2
FTC 12.0 ± 3.0 1.03 ± 0.23 11.6
3TC 6.93 ± 2.87 0.53 ± 0.01 13.1
NVP 1.41 ± 0.85 0.063 ± 0.04 22.4
AZT 2.3 ± 1.6 0.074 ± 0.04 31.1
a Concentration required to keep viral rebound at 50% for 24 h after 
removal of inhibitor
b Concentration required to protect 50% of cells from infection for 24 
h after removal of inhibitorAIDS Research and Therapy 2009, 6:5 http://www.aidsrestherapy.com/content/6/1/5
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pharmacodynamic property of an inhibitor. The persist-
ence assay may complement EC50, IQ, and IIP in the selec-
tion of combination regimen (e.g., the NTRI-backbone)
and better predict clinical effect of novel inhibitors. In
addition, the discovery of novel drugs with superior per-
sistence of anti-HIV activity may change viral dynamics in
treatment-experienced individuals. Further studies using
primary cells to validate our findings are needed.
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